Atypical Parkinsonism clinical trials at UCSF

2 research studies open to eligible people

Atypical parkinsonism refers to disorders that mimic Parkinson's disease but are distinct. UCSF is exploring the safety and effectiveness of AMX0035 for Progressive Supranuclear Palsy. UCSF is also running a study to see if zoledronic acid can reduce fractures in Parkinson's patients.

Showing trials for

  • AMX0035 and Progressive Supranuclear Palsy

    open to eligible people ages 40-80

    A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.

    San Francisco, California and other locations

  • Parkinson's and Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    San Francisco, California and other locations

Last updated: